In this talk, I will discuss the highs and lows of data interpretation for metabolomists, and share the latest tools provided by biocrates to unleash the full impact of metabolomics for research and health.

Metabolomics is vital for understanding biological processes but analyzing complex data is challenging. This talk covers advances in computational tools like FERMO and msFeaST, which streamline data analysis, linking phenotypes to metabolomic profiles.

INSERT EXCERPT

This talk presents a recent study that combined metabolomic, metagenomic, and metabolic modeling to assess the prevalence of bacterial auxotrophies in the human gut and their correlation with the host’s metabolome.

Gut regionality is key in physiology studies but often ignored in metabolome research. It’s crucial for understanding metabolic changes, especially during pregnancy.

The study analyzed pre-diagnostic serum samples from healthy women in the Norwegian Trøndelag Health Study (HUNT2 study) to identify molecular biomarkers linked to breast cancer risk.

In this presentation Prof. Ose highlights the research conducted by an international consortium focusing on colorectal cancer (CRC) patients at the time of diagnosis.

Metabolomics, the comprehensive analysis of metabolites in vivo, has contributed significantly to research on the search for diagnostic biomarkers for various diseases.

Immunometabolism is an important component to the pathophysiology of inflammatory bowel diseases and thus may serve the purpose of contributing to better and more personalized therapy decisions. While several metabolic pathways contribute, the talk puts special emphasis on the metabolism of the essential amino acid tryptophan.

Pancreatic ductal adenocarcinoma (PDAC) is expected to be the second most deadly cancer by 2040, owing to the high incidence of metastatic disease and limited responses to treatment. Less than half of all patients respond to the primary treatment for PDAC, chemotherapy, and genetic alterations alone cannot explain this. Using shotgun metagenomic sequencing and metabolomic screening, we show that the microbiota-derived tryptophan metabolite indole-3-acetic acid (3-IAA) is enriched in patients who respond to treatment.

Metabolomics can be used to develop tools to help guide therapy decisions in multiple ways, e.g. predict whether a drug will be effective, choose the best course of therapy, or monitor therapies along the patient journey.

With the second edition of this cohort event Pan-cohort studies – The future of population health- we are looking forward to expand into the physical spaces and stretch the scope beyond metabolomics.

During this webinar you can learn about WebIDQ, the next evolution of biocrates’ metabolomics workflow management and data processing software. With an intuitive user interface, WebIDQ guides users from sample registration through quantification and reporting.

During this webinar you can learn the benefits and possibilites of using the biocrates Quantitative metabolomics database (QMDB)

During this webinar you can learn how microbiota impact the gut-immune axis through short- and medium-chain fatty acids

Cancer cells adjust metabolic program to their specific energy needs in response to challenging microenvironment, which frequently results in cancer cell “addiction” to certain metabolic pathways. Those “addictions” could be deployed as treatment targets. Metabolic profiling by providing quantitative measure of metabolic processes offers attractive strategy for investigation of not only cancer cells “addictions” but also metabolic switches contributing to treatment resistance.